预约演示
更新于：2026-09-04
Norursodeoxycholic acid
去甲熊去氧胆酸
更新于：2026-09-04
概要
基本信息
药物类型 小分子化药 |
别名 24-norursodeoxycholic acid、Nor-ursodeoxycholic acid、Norucholic Acid + [4] |
作用方式 抑制剂 |
作用机制 胆固醇抑制剂 |
在研适应症 |
非在研适应症 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 印度 (2025-08-14), |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (澳大利亚) |
登录后查看时间轴
结构/序列
分子式C23H38O4 |
InChIKeyQYYDXDSPYPOWRO-JHMCBHKWSA-N |
CAS号99697-24-2 |
关联
15
项与 去甲熊去氧胆酸 相关的临床试验CTIS2025-523778-17-00
A study to compare how the body absorbs 4 different forms of norucholic acid medicine (tablets, granules, and capsules) when taken with or without food in healthy adults
CTRI/2026/05/110771
A Phase IV Open Label Single Arm Study Evaluating Safety and Effectiveness ofNorUrsodeoxycholic Acid 1500 mg in participants with Non Alcoholic Fatty Liver Disease - NA
CTRI/2026/02/102886
An Interventional Open label Three Arm Randomized MultiCenter Parallel Group Comparative Evaluation of Safety and Effectiveness of Nor-Ursodeoxycholic Acid 1500 mg versus Ursodeoxycholic Acid 900 mg versus Saroglitazar 4 mg in Participants with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) - NIL
100 项与 去甲熊去氧胆酸 相关的临床结果
登录后查看更多信息
100 项与 去甲熊去氧胆酸 相关的转化医学
登录后查看更多信息
100 项与 去甲熊去氧胆酸 相关的专利（医药）
登录后查看更多信息
108
项与 去甲熊去氧胆酸 相关的文献（医药）2026-07-01Journal of Clinical and Experimental Hepatology
Nor-ursodeoxycholic Acid for Metabolic Dysfunction-associated Steatotic Liver Disease: Is There Enough Evidence for Clinical Use? A Critique of a Phase III Trial and Regulatory Endorsement of the Drug
Letter
作者: Kulkarni, Anand V ; Kumar, Ashish ; Goel, Amit ; Aggarwal, Rakesh ; Kumar, Karan ; Shukla, Akash ; Saraswat, Vivek ; Duseja, Ajay ; Dhiman, R K ; Shalimar
2026-05-01Molecular Metabolism
The conjugation-resistant bile acid norUDCA cures liver fibrosis but impairs systemic energy metabolism
Article
作者: Fuerst, Rita ; Manka Fuh, Marceline ; Heine, Markus ; Vargek, Martin ; Rolle-Kampczyk, Ulrike ; Evangelakos, Ioannis ; Gunasekaran, Karthikeyan ; Engelmann, Beatrice ; Worthmann, Anna ; Scheja, Ludger ; Kumari, Manju ; Breinbauer, Rolf ; Hansen, Arne ; Graute, Sebastian ; Moustafa, Tarek ; Heeren, Joerg ; Saleem, Umber ; Rohde, Julia K ; Verkade, Esther ; Schwinge, Dorothee ; Zaufel, Alex ; de Boer, Jan Freark ; Schlein, Christian ; von Bergen, Martin ; Kuipers, Folkert
Bile acids (BAs) play an important role in systemic metabolic improvements following bariatric surgery. In this study, we found that orally administered norursodeoxycholic acid (norUDCA), a conjugation-resistant C23 derivative of naturally occurring UDCA, accumulated in peripheral organs including heart and brown adipose tissue (BAT). Moreover, norUDCA decreased systemic levels of endogenous conjugated BAs, while increasing unconjugated BAs. Notably, in addition to beneficial effects in a cholestatic liver disease model, norUDCA also lowered plasma glucose and fat mass in mice, suggesting that this BA derivative could be repurposed for treating obesity-associated cardiometabolic diseases. Metabolic energy expenditure studies, however, revealed that norUDCA-treated mice have impaired BAT capacity and developed intolerance to cold stress, a phenotype exacerbated in mice lacking adipose ATGL-dependent lipolysis. Transcriptomic and metabolic analyses demonstrated tissue remodeling in heart and BAT that involved pronounced changes in energy substrate utilization, including enhanced cardiac glucose uptake and higher ketone body utilization in BAT. Importantly, co-administration of a low-carb diet prevented cold stress-induced metabolic deficits. Mechanistic studies in human engineered heart tissue indicated that norUDCA compromised contractile function. In conclusion, these data suggest that conjugation-resistant BA derivatives like norUDCA impair myocardial and BAT energetics by altering glucose, lipid, and energy metabolism, particularly during catabolic cold stress conditions.
2025-12-01GUT
24-Nor-ursodeoxycholic acid: a novel treatment targeting T-cell-mediated immune dysregulation in primary sclerosing cholangitis and beyond
Article
作者: Wu, William Ka Kei ; Tan, Likai
100 项与 去甲熊去氧胆酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 代谢功能障碍相关的脂肪肝病 | 印度 | 2025-08-14 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性硬化性胆管炎 | 临床3期 | 奥地利 | 2017-08-24 | |
| 慢性肝病 | 临床2期 | 奥地利 | 2022-04-29 | |
| 原发性胆汁性胆管炎 | 临床2期 | 奥地利 | 2022-04-29 | |
| 代谢功能障碍相关脂肪性肝炎 | 临床2期 | 匈牙利 | 2019-04-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,500 | 衊顧夢繭顧鑰顧願艱鹽(遞憲製壓糧艱窪壓鹽願) = Adverse events were generally balanced between NCA patients with and without UDCA 壓構齋製壓製鹽窪糧糧 (積築夢網衊齋醖廠築構 ) 更多 | 积极 | 2026-05-27 | |||
Placebo + Ursodeoxycholic acid | |||||||
临床2期 | 159 | norUDCA 500mg/d | 選範憲觸簾鬱積鏇繭鑰(觸繭繭顧顧廠範鑰構餘) = 艱遞鹽廠選構糧壓積糧 遞願獵積淵簾襯餘艱鹹 (憲憲網糧糧糧觸糧艱鏇 ) | - | 2017-09-01 | ||
norUDCA 1,000mg/d | 選範憲觸簾鬱積鏇繭鑰(觸繭繭顧顧廠範鑰構餘) = 構積製鏇鬱選鬱醖鬱壓 遞願獵積淵簾襯餘艱鹹 (憲憲網糧糧糧觸糧艱鏇 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用